An in vitro and in silico identification of antibiofilm small molecules from seawater metaclone SWMC166 against Vibrio cholerae O1

2018 ◽  
Vol 39 ◽  
pp. 14-24 ◽  
Author(s):  
Murugan Rajalaxmi ◽  
Rajamohamed Beema Shafreen ◽  
Karuppiah Chithiraiselvi ◽  
Shunmugiah Karutha Pandian
2018 ◽  
Vol 120 (4) ◽  
pp. 5519-5530 ◽  
Author(s):  
Hetal Damani Shah ◽  
Dhananjaya Saranath ◽  
Soma Das ◽  
Prashant Kharkar ◽  
Anjali Karande

2014 ◽  
Vol 27 (5) ◽  
pp. 873-881 ◽  
Author(s):  
Tina Ritschel ◽  
Susanne M. A. Hermans ◽  
Marieke Schreurs ◽  
Jeroen J. M. W. van den Heuvel ◽  
Jan B. Koenderink ◽  
...  

BMC Genomics ◽  
2015 ◽  
Vol 16 (1) ◽  
Author(s):  
Tao Ke ◽  
Huihui Cao ◽  
Junyan Huang ◽  
Fan Hu ◽  
Jin Huang ◽  
...  

2011 ◽  
Vol 17 (12) ◽  
pp. 3063-3073 ◽  
Author(s):  
Amit Nargotra ◽  
Sujata Sharma ◽  
Mohd Iqbal Alam ◽  
Zabeer Ahmed ◽  
Asha Bhagat ◽  
...  

2018 ◽  
Vol 120 (3) ◽  
pp. 3353-3361 ◽  
Author(s):  
Phongphat Obounchoey ◽  
Lueacha Tabtimmai ◽  
Praphasri Suphakun ◽  
Kannika Thongkhao ◽  
Chatchakorn Eurtivong ◽  
...  

2001 ◽  
Vol 69 (1) ◽  
pp. 435-445 ◽  
Author(s):  
Jutta Nesper ◽  
Crystal M. Lauriano ◽  
Karl E. Klose ◽  
Dagmar Kapfhammer ◽  
Anita Kraiß ◽  
...  

ABSTRACT Recently we described the isolation of spontaneous bacteriophage K139-resistant Vibrio cholerae O1 El Tor mutants. In this study, we identified phage-resistant isolates with intact O antigen but altered core oligosaccharide which were also affected in galactose catabolism; this strains have mutations in the galU gene. We inactivated another gal gene, galE, and the mutant was also found to be defective in the catabolism of exogenous galactose but synthesized an apparently normal lipopolysaccharide (LPS). Both gal mutants as well as a rough LPS (R-LPS) mutant were investigated for the ability to colonize the mouse small intestine. The galU and R-LPS mutants, but not thegalE mutant, were defective in colonization, a phenotype also associated with O-antigen-negative mutants. By investigating several parameters in vitro, we could show that galU and R-LPS mutants were more sensitive to short-chain organic acids, cationic antimicrobial peptides, the complement system, and bile salts as well as other hydrophobic agents, indicating that their outer membrane no longer provides an effective barrier function. O-antigen-negative strains were found to be sensitive to complement and cationic peptides, but they displayed significant resistance to bile salts and short-chain organic acids. Furthermore, we found thatgalU and galE are essential for the formation of a biofilm in a spontaneous phage-resistant rugose variant, suggesting that the synthesis of UDP-galactose via UDP-glucose is necessary for biosynthesis of the exopolysaccharide. In addition, we provide evidence that the production of exopolysaccharide limits the access of phage K139 to its receptor, the O antigen. In conclusion, our results indicate involvement of galU in V. cholerae virulence, correlated with the observed change in LPS structure, and a role for galU and galE in environmental survival of V. cholerae.


2014 ◽  
Vol 86 (5) ◽  
pp. 593-608 ◽  
Author(s):  
Ashley J. Parks ◽  
Michael P. Pollastri ◽  
Mark E. Hahn ◽  
Elizabeth A. Stanford ◽  
Olga Novikov ◽  
...  

2020 ◽  
Author(s):  
Sandra Smieszek ◽  
Bart Przychodzen ◽  
Vasilios Polymeropoulos ◽  
Christos Polymeropoulos ◽  
Mihael Polymeropoulos

ACE2 is a key receptor for SARS-CoV-2 cell entry. Binding of SARS-Cov-2 to ACE2 involves the viral Spike protein. The molecular interaction between ACE2 and Spike has been resolved. Interfering with this interaction might be used in treating patients with COVID-19. Inhibition of this interaction can be attained via multiple routes: here we focus on identifying small molecules that would prevent the interaction. Specifically we focus on small molecules and peptides that have the capacity to effectively bind the ACE2: RBD contact domain to prevent and reduce SARS-CoV-2 entry into the cell. We aim to identify molecules that prevent the docking of viral spike protein (mediated by RBD) onto cells expressing ACE2, without inhibiting the activity of ACE2. We utilize the most recent ACE2-RBD crystallography resolved model (PDB-ID:6LZG). Based on animal susceptibility data we narrowed down our interest to the location of amino acid 34 (Histidine) located on ACE2. We performed an in silico screen of a chemical library of compounds with several thousand small molecules including FDA approved compounds. All compounds were tested for binding to the proximal binding site located close to histidine 34 on ACE2. We report a list of four potential small molecules that potentially have the capacity to bind target residue: AY-NH2, a selective PAR4 receptor agonist peptide (CAS number: 352017-71-1), NAD+ (CAS number: 53-84-9), Reproterol, a short-acting β2 adrenoreceptor agonist used in the treatment of asthma (CAS number: 54063-54-6), and Thymopentin, a synthetic immune-stimulant which enhances production of thymic T cells (CAS number: 69558-55-0). The focus is on a High Throughput Screen Assay (HTSA), or in silico screen, delineating small molecules that are selectively binding/masking the crucial interface residue on ACE2 at His34. Consequently, inhibiting SARS-CoV-2 binding to host ACE2 and viral entry is a potent strategy to reduce cellular entry of the virus. We suggest that this anti-viral nature of this interaction is a viable strategy for COVID19 whereas the small molecules including peptides warrant further in vitro screens.


Sign in / Sign up

Export Citation Format

Share Document